LGD 2941

Drug Profile

LGD 2941

Alternative Names: LGD-2226; LGD-2941; LGD122941

Latest Information Update: 24 Jan 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ligand Pharmaceuticals
  • Class Aminoquinolines; Small molecules
  • Mechanism of Action Selective androgen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cachexia; Female sexual dysfunction; Hypogonadism; Male sexual dysfunction; Menopausal syndrome; Osteoporosis

Most Recent Events

  • 18 Jun 2008 Pharmacokinetics and adverse events data from a Phase-I trial in healthy volunteers presented at the 90th Annual Meeting of the Endocrine Society (ENDO-2008)
  • 11 Oct 2007 Preclinical data added to the Musculoskeletal Disorders and Women's Health pharmacodynamics sections
  • 11 Sep 2007 Phase I development is ongoing in Osteoporosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top